SV Health Investors

SV Health Investors investment thesis

Rondo Therapeutics is a biopharmaceutical company breaking new ground in cancer therapy. The company’s mission is to advance bispecific antibody therapies that address unmet needs in the treatment of solid tumors. Rondo is developing a new class of bispecific antibodies designed to harness the immune system to target and eliminate tumors with enhanced safety. Rondo Therapeutics is supported by Canaan Partners, Red Tree Venture Capital, Johnson & Johnson, SV Health Investors, and Novo Holdings. In addition to RNDO-564, the company’s pipeline includes immune-engaging bispecifics for a range of solid tumors, including ovarian, endometrial, and renal cancers. For more information, please visit www.rondotx.com .

SV Health Investors team (22)

Partners and principals at SV Health Investors:

• Houman Ashrafian — sweet spot $1.5M
• Alex Badamchi-Zadeh — sweet spot $1.5M
• Josh Baker — sweet spot $1.5M
• Michael Balmuth — sweet spot $1.5M
• Laurence Barker — sweet spot $1.5M
• Jonathan Behr — sweet spot $1.5M
• Kate Bingham — sweet spot $1.5M
• Rebecca Canter — sweet spot $1.5M
• Charles Dunn — sweet spot $1.5M
• Tom Flynn — sweet spot $1.5M
• William Gerard — sweet spot $1.5M
• Eugene Hill — sweet spot $1.5M
• Christian Jung — sweet spot $1.5M
• Jack Kenney — sweet spot $1.5M
• Dirk Landgraf — sweet spot $1.5M
• Paul LaViolette — sweet spot $1.5M
• Megan MacDonagh — sweet spot $1.5M
• Greg Madden — sweet spot $1.5M
• Niyoshi Patel — sweet spot $1.5M
• Marek Poszepczynski — sweet spot $1.5M
• Mike Ross — sweet spot $1.5M
• Alexander Sinclair-Wilson — sweet spot $1.5M

SV Health Investors portfolio companies

Companies listed on SV Health Investors's public materials include: Strategy Therapeutics Healthcare Growth Medtech, Strategy, Therapeutics, Healthcare Growth, Medtech, People, Portfolio, News, SV8 Biotech Fund, SV7+ Growth Fund, Dementia Discovery Fund-2, SV Biotech Crossover Opportunities Fund, SV7 Impact Medicine Fund, SV7 Growth Fund, Dementia Discovery Fund-1, SV Life Sciences Funds 5-6, SV Fund IV Continuation Fund, SV Life Sciences Funds 3-4, Current Deals, United States, Rest of World, UK, Europe, Exited Investments (M&A, IPO & Recapitalization), Accelecare Holdings, Achillion Pharmaceuticals, AeroCare Holdings, Inc., Affinium Pharmaceuticals, Alantos Pharmaceuticals, Alector, Aligned Telehealth Inc, Allegiance Hospice Group, AllianceCare, Allos Therapeutics, Altura Medical, American Well, Aptiv Solutions, AqueSys, Argonaut Technologies, Arsanis Biosciences, Atopix Therapeutics Limited, Auxilium Pharmaceuticals, Avitide, AvroBio, Inc, Axys Pharmaceuticals, BardyDx, BioCore Holdings (BioClinica), Broadlane, Cadent Technologies, Caraway Therapeutics, Cardiac Support Systems, CardioKinetix, CardioMind, Celerion, Cellutions, Cellzome Limited, Cerebral Vascular Applications, CHF Solutions, Cibiem, Cognis Holding.

Is SV Health Investors a fit for your round?

Upload your pitch deck and see whether anyone at SV Health Investors appears in your top matches.